How Brain-on-a-Chip Technology Is Transforming the Study and Treatment of Neurological Disorders

Natalie Orlov

Neurological disorders, including Alzheimer’s disease, Parkinson’s disease, epilepsy, and  glioblastoma, affect hundreds of millions of people worldwide and remain among the most  difficult diseases to treat. One of the greatest obstacles in neuroscience is the inability to  accurately model the human brain in a laboratory. Traditional two-dimensional cell cultures fail  to recreate the complex interactions between neurons, while animal models often do not fully  reflect human brain physiology, leading to promising treatments that fail during clinical trials  (1,2). To address these challenges, researchers have developed brain-on-a-chip technology, an  innovative form of organ-on-a-chip engineering that recreates key features of the human brain  within a miniature microfluidic device. 

Brain-on-a-chip systems combine living human brain cells with precisely engineered channels  that continuously deliver nutrients, oxygen, and biochemical signals. These devices provide  scientists with a controlled environment that closely mimics the brain’s natural conditions,  allowing researchers to observe how neurons communicate, how diseases develop, and how  potential therapies affect human brain tissue in real time (2,3). As advances in stem cell biology,  tissue engineering, and microfabrication continue, brain-on-a-chip technology is emerging as 

one of the most promising tools for improving neurological research, accelerating drug  discovery, and advancing personalized medicine. 

How Brain-on-a-Chip Technology Works 

Brain-on-a-chip devices are part of a broader family of organ-on-a-chip systems, which use  microfluidic engineering to replicate the structure and function of human organs. Each chip is  typically only a few centimeters in size and contains microscopic channels through which  nutrient rich fluid flows, simulating the circulation of blood throughout the body (2). These  channels allow scientists to expose cells to realistic mechanical and chemical conditions that  cannot be recreated using conventional laboratory cultures. 

To create a brain-on-a-chip model, researchers often begin with human induced pluripotent  stem cells (iPSCs). These cells can be generated from adult skin or blood samples and  reprogrammed into nearly any cell type, including neurons, astrocytes, oligodendrocytes, and  microglia, the major cell populations found within the human brain (3,4). Because iPSCs can be  obtained from individual patients, scientists can generate brain models that reflect a person’s  unique genetic background, making personalized disease modeling possible. 

Unlike traditional cell cultures, brain-on-a-chip platforms allow multiple brain cell types to interact  within a three dimensional environment while receiving continuous fluid flow. Many advanced  devices also incorporate models of the blood brain barrier, a highly selective network of  endothelial cells that regulates which substances enter the brain from the bloodstream (5).  Since many neurological drugs fail because they cannot cross this barrier, incorporating it into  laboratory models enables researchers to evaluate both drug effectiveness and drug delivery  before human clinical trials. 

Modern brain-on-a-chip systems also integrate sensors capable of monitoring electrical activity,  oxygen consumption, inflammation, and cellular metabolism without disturbing the tissue (6).  These real time measurements provide valuable insight into how neurons form networks,  transmit signals, and respond to disease or experimental treatments. Compared with  conventional laboratory methods, these platforms offer a more relevant representation of the  living human brain while requiring fewer experimental animals.

Applications in Neurological Disease Research 

One of the most significant advantages of brain-on-a-chip technology is its ability to recreate the  cellular environment of neurological diseases using human cells rather than animal tissue.  Researchers can observe how diseases develop over time, identify the earliest biological  changes, and evaluate potential treatments under conditions that closely resemble those found  in the human brain (3,6). Because many neurological disorders involve interactions among  multiple cell types, these platforms provide a more comprehensive understanding of disease  mechanisms than traditional cell cultures. 

Alzheimer’s Disease 

Alzheimer’s disease is the most common cause of dementia and is characterized by the  accumulation of amyloid-beta plaques, neurofibrillary tangles composed of tau protein, chronic  inflammation, and progressive neuronal loss (7). Although scientists have studied Alzheimer’s  disease for decades, many drugs that appeared successful in animal models ultimately failed  during human clinical trials, highlighting the need for more accurate laboratory models.

Brain-on-a-chip technology has enabled researchers to reproduce several hallmark features of  Alzheimer’s disease using neurons derived from patients carrying genetic risk factors. These  models demonstrate the formation of amyloid beta deposits, abnormal tau protein accumulation,  activation of immune cells known as microglia, and disruptions in communication between  neurons (7,8). Because these disease processes can be monitored continuously, investigators  are able to evaluate how experimental medications influence disease progression over weeks or  months. Some studies have also incorporated miniature blood-brain barrier models, allowing  researchers to determine whether therapeutic compounds can successfully reach brain tissue  before advancing to clinical trials (5,8). 

Parkinson’s Disease 

Parkinson’s disease affects more than 10 million people worldwide and primarily results from  the gradual degeneration of dopamine-producing neurons within the substantia nigra (9).  Current treatments help relieve symptoms but do not stop the underlying neurodegenerative  process. 

Brain-on-a-chip models generated from patients with Parkinson’s disease have reproduced  several important pathological features, including alpha-synuclein protein aggregation,  mitochondrial dysfunction, oxidative stress, and impaired neuronal communication (9,10). By  using cells obtained directly from individual patients, researchers can investigate why disease  progression varies among individuals and evaluate whether specific therapies produce  personalized responses. These patient specific models represent an important step toward  precision medicine, where treatments may eventually be tailored to each person’s unique  biology rather than relying solely on generalized treatment strategies. 

Epilepsy and Other Neurological Disorders 

Brain-on-a-chip platforms are also being used to investigate epilepsy, a disorder characterized  by abnormal electrical activity within networks. Traditional laboratory models often struggle to  replicate the complex communication between neurons that gives rise to seizures. In contrast, brain-on-a-chip devices allow scientists to monitor spontaneous electrical activity in real time  using integrated microelectrodes (6). Researchers can evaluate how seizure activity begins,  spreads through neural circuits, and responds to anticonvulsant medications under controlled  conditions. 

Beyond epilepsy, these systems are being applied to study amyotrophic lateral sclerosis (ALS),  multiple sclerosis, traumatic brain injury, autism spectrum disorders, Huntington’s disease, and  viral infections affecting the nervous system (3,6). As new cell types and biomaterials continue  

to be incorporated into these devices, researchers are creating sophisticated models capable of  reproducing complex neurological conditions that were previously difficult to study outside the  human body. 

Personalized Medicine and Drug Discovery

Perhaps the most exciting application of brain-on-a-chip technology is its potential role in  personalized medicine. Since induced pluripotent stem cells can be generated from a specific  patient’s skin or blood cells, researchers can construct individualized brain models that retain  the patient’s genetic characteristics (4). Physicians may eventually use these personalized chips  to determine which medications are most effective for a particular individual before treatment  begins. 

This approach could substantially reduce the time and cost associated with drug development.  Developing a new neurological drug often requires more than a decade of research and billions  of dollars in investment, yet many promising candidates fail during late stage clinical trials  because they do not produce the same results in humans as they did in laboratory animals  (2,5). Brain-on-a-chip platforms provide a more human-relevant testing system that may  improve the identification of safe and effective therapies while reducing unnecessary clinical  failures. Although these devices are not expected to completely replace animal models in the  immediate future, they have the potential to significantly improve the efficiency, accuracy, and  standards of neurological research. 

Advantages of Brain-on-a-Chip Technology 

Brain-on-a-chip technology offers several advantages over traditional laboratory models.  Conventional two-dimensional cell cultures lack the three-dimensional architecture and complex  interactions found in the human brain, while animal models often fail to accurately predict how  therapies will perform in humans due to important biological differences between species (2,5).  These limitations contribute to the high failure rate of neurological drugs during clinical trials. 

By incorporating human cells, microfluidic circulation, and multiple interacting brain cell types,  brain-on-a-chip systems provide a more physiologically relevant environment for studying  neurological disorders. Researchers can observe cellular communication, inflammation,  electrical signaling, and responses to experimental treatments in real time without destroying  the tissue (3,6). This continuous monitoring allows scientists to detect small biological changes  that might otherwise be overlooked. 

These devices also support the principles of the 3R’s Replacement, Reduction, and Refinement,  which aim to minimize the use of animals in scientific research. Although animal studies remain  necessary for many aspects of biomedical research, brain-on-a-chip technology may reduce the  number of animals required while providing data that more closely reflects human biology (2). In  

addition, because these systems require only small amounts of cells and experimental  compounds, they can lower research costs and speed up the screening of potential drug  candidates. 

Current Challenges

Despite their promise, brain-on-a-chip devices are still evolving and face several important  limitations. The human brain contains approximately 86 billion neurons connected through an  extraordinarily complex network of synapses, blood vessels, immune cells, and supporting  tissues (11). Current laboratory models can reproduce only a small amount of this complexity. 

Another challenge is standardization. Different research laboratories often use different chip  designs, cell sources, culture conditions, and measurement techniques, making it difficult to  directly compare experimental results across studies (3). Scientists are actively working to  establish standardized manufacturing protocols and quality-control guidelines that will improve  reproducibility and facilitate regulatory approval. 

Long-term maintenance also remains difficult. Keeping human brain tissue alive and functioning  for extended periods requires carefully controlled environmental conditions, and even slight  changes in temperature, nutrient delivery, or oxygen levels can affect experimental outcomes  (6). Furthermore, while patient-derived stem cells allow personalized disease modeling,  generating these cells is time consuming and expensive, limiting widespread clinical  implementation. 

Looking Toward the Future 

Rapid advances in tissue engineering, stem cell biology, artificial intelligence, and  microfabrication are expected to further improve brain-on-a-chip technology over the coming  decade. Researchers are developing increasingly sophisticated devices that integrate multiple  regions of the brain, vascular systems, and components to better mimic the interactions that  occur within the nervous system (3,5). 

Artificial intelligence is also beginning to enhance brain-on-a-chip research by analyzing large  datasets generated from continuous cellular monitoring. Machine learning algorithms can  identify patterns in electrical activity, protein expression, and cellular behavior that may predict  disease progression or therapeutic responses more accurately than traditional analytical  methods (12). Combining AI with specific brain chips may eventually allow physicians to test  several treatment options in the laboratory before selecting the therapy most likely to benefit an  individual patient. 

Although significant technical and regulatory challenges remain, brain-on-a-chip technology  represents one of the most promising innovations in modern neuroscience. By creating  laboratory models that more accurately replicate the human brain, these devices have the  potential to improve our understanding of neurological diseases, accelerate the development of  safer and more effective medications, reduce reliance on animal testing, and advance the future  of personalized medicine. 

Brain-on-a-chip technology is transforming the study of neurological disorders by providing  researchers with a more realistic model of the human brain than has previously been possible.  Through the integration of human stem cell-derived brain tissue, microfluidic engineering, and  advanced sensing technologies, these devices enable scientists to investigate disease 

mechanisms, evaluate new therapies, and explore personalized treatment strategies. While  current models cannot yet replicate the full complexity of the human brain, ongoing  technological advances continue to improve their accuracy and clinical relevance. As research  progresses, brain-on-a-chip platforms are expected to become an increasingly important tool in  neuroscience, offering new opportunities to develop treatments for devastating neurological  diseases and ultimately improve patient care. 

References  

Azevedo, Frederico A. C., et al. “Equal Numbers of Neuronal and Nonneuronal Cells Make the  Human Brain an Isometrically Scaled-Up Primate Brain.” Journal of Comparative Neurology, vol.  513, no. 5, 2009, pp. 532–541. 

“Microfluidic “Mini-Brains”: Keeping up with the Brain-On-Chip Technology.” Elveflow, 19  Dec. 2024, elveflow.com/microfluidic-reviews/microfluidic-brain-on-chip/. (Source for  comparative figure) 

Choi, Se Hoon, et al. “A Three-Dimensional Human Neural Cell Culture Model of Alzheimer’s  Disease.” Nature, vol. 515, no. 7526, 2014, pp. 274–278. 

De Strooper, Bart, and Eric Karran. “The Cellular Phase of Alzheimer’s Disease.” Cell, vol. 164,  no. 4, 2016, pp. 603–615. 

Humpel, Christian. “Organotypic Brain Slice Cultures: A Review.” Neuroscience, vol. 305, 2015,  pp. 86–98. 

Ingber, Donald E. “Human Organs-on-Chips for Disease Modelling, Drug Development and  Personalized Medicine.” Nature Reviews Genetics, vol. 23, no. 8, 2022, pp. 467–491. 

Ingber, Donald E. “Is It Time for Reviewer 3 to Request Human Organ Chip Experiments  Instead of Animal Validation Studies?” Advanced Science, vol. 7, no. 22, 2020, Article 2002030. 

Kim, Jiyoon, Bon-Kyoung Koo, and Jürgen A. Knoblich. “Human Organoids: Model Systems for  Human Biology and Medicine.” Nature Reviews Molecular Cell Biology, vol. 21, no. 10, 2020,  pp. 571–584. 

Low, Leslie A., et al. “Organs-on-Chips: Into the Next Decade.” Nature Reviews Drug Discovery,  vol. 20, no. 5, 2021, pp. 345–361. 

Park, Tae-Eun, et al. “Hypoxia-Enhanced Blood-Brain Barrier Chip Recapitulates Human Barrier  Function and Shuttling of Drugs and Antibodies.” Nature Communications, vol. 10, 2019, Article  2621.

Poewe, Werner, et al. “Parkinson Disease.” Nature Reviews Disease Primers, vol. 3, 2017,  Article 17013. 

Rodrigues, Raquel O., Su-Ryon Shin, and Manuel Bañobre-López. “Brain-on-a-Chip: An  Emerging Platform for Studying the Nanotechnology-Biology Interface for Neurodegenerative  Disorders.” Journal of Nanobiotechnology, vol. 22, 2024, article 573, Springer Nature, 18 Sept.  2024, doi:10.1186/s12951-024-02720-0. (Source for comparative figure) 

Ronaldson, Patrick T., and Thomas P. Davis. “Regulation of Blood-Brain Barrier Integrity by  Microvascular Endothelial Cells.” Nature Reviews Neuroscience, vol. 21, no. 4, 2020, pp. 197– 210. 

Smits, Lianne M., et al. “Modeling Parkinson’s Disease in Midbrain-Like Organoids.” npj  Parkinson’s Disease, vol. 5, 2019, Article 5. 

Takahashi, Kazutoshi, and Shinya Yamanaka. “Induction of Pluripotent Stem Cells from Mouse  Embryonic and Adult Fibroblast Cultures by Defined Factors.” Cell, vol. 126, no. 4, 2006, pp.  663–676. 

Vatine, Galina D., et al. “Human iPSC-Derived Blood-Brain Barrier Chips Enable Disease  Modeling and Personalized Medicine Applications.” Cell Stem Cell, vol. 24, no. 6, 2019, pp.  995–1005. 

Zhang, Bo, et al. “Advances in Organ-on-a-Chip Engineering.” Nature Reviews Materials, vol. 3,  2018, pp. 257–278.

Assessed and Endorsed by the MedReport Medical Review Board